Home
ABOUT US
Overview
Business Model
Board of Directors
Management Team
History & Milestones
Corporate Social Responsibility
R & D PIPELINE
INVESTORS
Investor Overview
Financial Reports
Shareholders’ Meetings
Events & Presentations
NEWS
CAREERS
CONTACT
EN
中文版
NEW DRUGS FOR THE TREATMENT OF CANCER
PharmaEngine
We Race With You
DISCOVER MORE
CANCER TREATMENT PRODUCTS
ONIVYDE
A Revolutionary Durg
DISCOVER ONIVYDE
NEW CONCEPTS FOR RADIOTHERAPY
Groundbreaking
Cancer Treatment
DISCOVER PEP503
History
&
Milestones
Onivyde
PharmaEngine Announce Its Partner, Nanobiotix, Received CE Mark Approval of PEP503 (NBTXR3, Hensify) for the Treatment of Locally Advanced Soft Tissue Sarcoma
2019/4/7
PharmaEngine Announces ONIVYDE® Obtained Reimbursement from Taiwan’s National Health Insurance Administration
2018/7/11
PharmaEngine Announces ONIVYDE® Launched in the Third Major European Country
2018/7/8
PEP503
R&D Pipeline
Events & Presentations
Organization
Our Partners
Contact Us
Go To Top